Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of rilzabrutinib in warm autoimmune hemolytic anemia
jRCT2031250270Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- Sep 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in warm autoimmune hemolytic anemia (wAIHA) comparing rilzabrutinib with placebo (2 arms). Primary endpoint: Durable hemoglobin response. Started Sep 2025; status: recruiting.
02
Drugs
rilzabrutinib
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on jRCT2031250270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250270.